Literature DB >> 11032193

Adult vaccination, part 2: vaccines for persons at high risk. Teaching Immunization for Medical Education (TIME) Project.

R K Zimmerman1, E R Ahwesh.   

Abstract

The morbidity and mortality from vaccine-preventable diseases are high among adults with underlying medical conditions. Influenza vaccination is recommended annually, optimally between October and mid-November, for all persons 50 years of age and older and those with cardiac disease with potential for altered hemodynamics, diabetes mellitus, immunocompromising conditions, pulmonary disease, or renal disease. This season, because of production delays, influenza vaccination campaigns are planned for November. Pneumococcal polysaccharide vaccination is recommended for all persons 65 years and older and for those with alcoholism, asplenia, cardiac disease, cirrhosis, diabetes mellitus, immunocompromising conditions, pulmonary disease, or chronic renal disease. Indications for hepatitis B vaccination include chronic renal disease and hemodialysis, as well as employment in health care or employment as a mortician or public safety officer. It is also recommended for homosexual men, those who have multiple sex partners or a sexually transmitted disease, and injection drug users.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032193

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  2 in total

1.  Routine immunization of adults in Canada: Review of the epidemiology of vaccine-preventable diseases and current recommendations for primary prevention.

Authors:  Michael D Parkins; Shelly A McNeil; Kevin B Laupland
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

2.  The Saudi Thoracic Society guidelines for influenza vaccinations.

Authors:  Mohammed O Zeitouni; Ali M Al Barrak; Mohamed S Al-Moamary; Nasser S Alharbi; Majdy M Idrees; Abdullah A Al Shimemeri; Mohamed S Al-Hajjaj
Journal:  Ann Thorac Med       Date:  2015 Oct-Dec       Impact factor: 2.219

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.